Reduction of Relapse after Unrelated Donor Stem Cell Transplantation by KIR-Based Graft Selection

Standard

Reduction of Relapse after Unrelated Donor Stem Cell Transplantation by KIR-Based Graft Selection. / Heidenreich, Silke; Kröger, Nicolaus.

In: FRONT IMMUNOL, Vol. 8, 2017, p. 41.

Research output: SCORING: Contribution to journalSCORING: Review articleResearch

Harvard

APA

Vancouver

Bibtex

@article{97888c3a1a0147379ee61b4a0a45c2ab,
title = "Reduction of Relapse after Unrelated Donor Stem Cell Transplantation by KIR-Based Graft Selection",
abstract = "Besides donor T cells, natural killer (NK) cells are considered to have a major role in preventing relapse after allogeneic hematopoietic stem cell transplantation (HSCT). After T-cell-depleted haploidentical HSCT, a strong NK alloreactivity has been described. These effects have been attributed to killer-cell immunoglobulin-like receptors (KIR). Abundant reports suggest a major role of KIR not only on outcome after haploidentical HSCT but also in the unrelated donor setting. In this review, we give a brief overview of the mechanism of NK cell activation, nomenclature of KIR haplotypes, human leukocyte antigen (HLA) groups, and distinct models for prediction of NK cell alloreactivity. It can be concluded that KIR-ligand mismatch seems to provoke adverse effects in unrelated donor HSCT with reduced overall survival and increased risk for high-grade acute graft-versus-host disease. The presence of activating KIR, as seen in KIR haplotype B, as well as the patient's HLA C1/x haplotype might reduce relapse in myeloid malignancies.",
keywords = "Journal Article, Review",
author = "Silke Heidenreich and Nicolaus Kr{\"o}ger",
year = "2017",
doi = "10.3389/fimmu.2017.00041",
language = "English",
volume = "8",
pages = "41",
journal = "FRONT IMMUNOL",
issn = "1664-3224",
publisher = "Lausanne : Frontiers Research Foundation",

}

RIS

TY - JOUR

T1 - Reduction of Relapse after Unrelated Donor Stem Cell Transplantation by KIR-Based Graft Selection

AU - Heidenreich, Silke

AU - Kröger, Nicolaus

PY - 2017

Y1 - 2017

N2 - Besides donor T cells, natural killer (NK) cells are considered to have a major role in preventing relapse after allogeneic hematopoietic stem cell transplantation (HSCT). After T-cell-depleted haploidentical HSCT, a strong NK alloreactivity has been described. These effects have been attributed to killer-cell immunoglobulin-like receptors (KIR). Abundant reports suggest a major role of KIR not only on outcome after haploidentical HSCT but also in the unrelated donor setting. In this review, we give a brief overview of the mechanism of NK cell activation, nomenclature of KIR haplotypes, human leukocyte antigen (HLA) groups, and distinct models for prediction of NK cell alloreactivity. It can be concluded that KIR-ligand mismatch seems to provoke adverse effects in unrelated donor HSCT with reduced overall survival and increased risk for high-grade acute graft-versus-host disease. The presence of activating KIR, as seen in KIR haplotype B, as well as the patient's HLA C1/x haplotype might reduce relapse in myeloid malignancies.

AB - Besides donor T cells, natural killer (NK) cells are considered to have a major role in preventing relapse after allogeneic hematopoietic stem cell transplantation (HSCT). After T-cell-depleted haploidentical HSCT, a strong NK alloreactivity has been described. These effects have been attributed to killer-cell immunoglobulin-like receptors (KIR). Abundant reports suggest a major role of KIR not only on outcome after haploidentical HSCT but also in the unrelated donor setting. In this review, we give a brief overview of the mechanism of NK cell activation, nomenclature of KIR haplotypes, human leukocyte antigen (HLA) groups, and distinct models for prediction of NK cell alloreactivity. It can be concluded that KIR-ligand mismatch seems to provoke adverse effects in unrelated donor HSCT with reduced overall survival and increased risk for high-grade acute graft-versus-host disease. The presence of activating KIR, as seen in KIR haplotype B, as well as the patient's HLA C1/x haplotype might reduce relapse in myeloid malignancies.

KW - Journal Article

KW - Review

U2 - 10.3389/fimmu.2017.00041

DO - 10.3389/fimmu.2017.00041

M3 - SCORING: Review article

C2 - 28228753

VL - 8

SP - 41

JO - FRONT IMMUNOL

JF - FRONT IMMUNOL

SN - 1664-3224

ER -